Clinical Trial

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-14.
Status change: Not Yet Recruiting → Recruiting 2025-11-24
Trial Details
NCT Number NCT07232654
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions LOCALLY ADVANCED CERVICAL CANCERS
Enrollment 30 participants
Start Date 2025-11-11
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-12-01